Clinical Trial Update: A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase II trial of TPI 287 for metastatic prostate cancer sponsored by Cortice Biosciences, Inc. has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• TPI-287

Snippet

Sponsor: Cortice Biosciences, Inc. | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED